Introducing Myriad myRisk™ Hereditary Cancer

Accurate knowledge of cancer risk. Actionable direction for patient management.
Knowing your patients’ hereditary cancer risk is critical

- Patient management recommendations are vastly different for those with a gene mutation associated with hereditary cancer risk
- Reduce the occurrence of a first or subsequent primary cancer with comprehensive hereditary cancer risk assessment

The Society of Gynecologic Oncology (SGO) recognizes the benefits of hereditary cancer panels¹

- Cost effective approach
- Improved efficiency
- More assurance in test results

Introducing Myriad myRisk™ Hereditary Cancer

Accurate knowledge

- A revolutionary hereditary cancer panel test that blends accurate genetic information and personal/family cancer history

Actionable direction

- Specific management based on medical society guidelines are provided for both positive and negative results

Industry-leading turnaround time

- Average 14 to 21 days
Mutation detection is increased 40% to 50% vs single-syndrome testing\textsuperscript{2,3}

- Single-syndrome testing may not detect important genes potentially overlapping in cancer risks\textsuperscript{4}
- Myriad myRisk includes 25 genes associated with eight major cancers based on heritable contribution and syndrome overlap
- Clinically actionable genes with established cancer risks are analyzed

Each cancer site is associated with multiple hereditary cancer syndromes. Gene panel includes: APC, ATM, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDKN2A, CDK4, CHEK2, EPCAM, MLH1, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, PTEN, RAD51C, RAD51D, SMAD4, STK11 and TP53.

**Associated Cancers\textsuperscript{*}**

<table>
<thead>
<tr>
<th>Genes</th>
<th>Breast</th>
<th>Ovarian</th>
<th>Colorectal</th>
<th>Endometrial</th>
<th>Melanoma</th>
<th>Pancreatic</th>
<th>Gastric</th>
<th>Prostate</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>BRCA1, BRCA2</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
</tr>
<tr>
<td>MLH1, MSH2, MSH6, PMS2, EPCAM</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
</tr>
<tr>
<td>STK11</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
</tr>
<tr>
<td>APC, BMPR1A, SMAD4</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
</tr>
<tr>
<td>MUTYH</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
</tr>
<tr>
<td>CDK4, CDKN2A</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
</tr>
<tr>
<td>TP53</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
</tr>
<tr>
<td>PTEN</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
</tr>
<tr>
<td>CDH1</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
</tr>
<tr>
<td>PALB2, ATM</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
</tr>
<tr>
<td>CHEK2</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
</tr>
<tr>
<td>NBN</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
</tr>
<tr>
<td>BARD1</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
</tr>
<tr>
<td>BRIP1, RAD51C</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
</tr>
<tr>
<td>RAD51D</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
<td>⬤</td>
</tr>
</tbody>
</table>

\*Gene mutations may be associated with other cancers and clinical features.

\*Large rearrangement only
The revolutionary report provides recommendations for managing patients based on genetic and familial cancer risks

Every report includes

- myRisk Genetic Result
- myRisk Management Tool
  - Medical society guidelines-based management considerations for both POSITIVE and NEGATIVE results
  - Management considerations may include:
    - Improved screening(s)
    - Preventive medication(s)
    - Risk-reducing procedure(s)
    - Considerations for family
    - Other management changes
  - Family history analysis (National Comprehensive Cancer Network [NCCN], the Claus model, International Cancer of the Pancreas Screening [CAPS], Amsterdam Criteria, and others)
Red flags to further assess hereditary cancer

An individual with a personal or family history of any 1 of the following:

<table>
<thead>
<tr>
<th>MULTIPLE</th>
<th>YOUNG</th>
<th>RARE</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 or more cancers on the same side of the family*</td>
<td>Any 1 of the following cancers at age 50 or younger</td>
<td>Any 1 of these rare presentations at any age</td>
</tr>
</tbody>
</table>

- Breast
- Prostate
- Melanoma
- Ovarian
- Pancreatic
- Colorectal
- Endometrial
- Gastric
- Other

Assessment criteria based on medical society guidelines. For these guidelines, go to www.MyriadPro.com/guidelines. Family members include first-, second-, and third-degree blood relatives on both the mother’s and the father’s sides. People of certain ancestries may have a greater risk for hereditary cancer syndromes (e.g., Ashkenazi Jewish ancestry).

*2 or more: breast/ovarian/prostate/pancreatic cancer; 2 or more: colorectal/endometrial/ovarian/gastric/pancreatic/other cancer (i.e., ureter/renal pelvis, biliary tract, small bowel, brain, sebaceous adenomas); 2 or more: melanoma/pancreatic cancer.

†Male breast cancer, triple-negative breast cancer.
‡Abnormal MSI/IHC, MSI-associated histology. Presence of tumor-infiltrating lymphocytes, Crohn’s-like lymphocytic reaction, mucinous/signet-ring differentiation, or medullary growth pattern.
§Other Lynch syndrome-associated cancers, 10 or more gastrointestinal adenomatous polyps.
¶Lynch syndrome-associated cancers include colon/rectal, uterine/endometrial, ovarian, stomach/gastric, kidney/urinary tract, biliary tract, small bowel, pancreas, brain, and sebaceous adenoma cancers.
Optimize patient care with accurate results you can trust

From Myriad, your trusted advisor

- World leader in hereditary cancer
- 20+ years of experience in cancer genetic testing
- 1 million+ patients tested
- 60,000+ providers have tested with Myriad

Best-in-class performance

>99.92% Analytical Sensitivity\(^5\)\
- Confidence as the gold standard for accuracy
- Validation studies show 100% concordance with Sanger sequencing and large rearrangement analysis

Test optimization

- Optimized NGS primer library design to increase test sensitivity and specificity
- Complemented by multiple customized techniques (eg, targeted microarray)

 Powered by myVision\(^\text{TM}\) variant classification

- Lifetime commitment for accurate variant interpretations
- >$1 million invested in developing variant classification techniques and a curated database supported by 30+ scientists
- >99% certainty for variant reclassification\(^6,7\)

\(^*\) >99.92% with lower bound 95% confidence interval.
References:


The Myriad advantage:
Best in class support

Financial support

• Most appropriate patients pay $0
• If your patients have concerns when they receive an invoice from Myriad, they can call the telephone number on the invoice. We guarantee that we will work together to reach a solution
• Uninsured and underinsured patients who meet specific financial and medical criteria are eligible for Myriad’s Financial Assistance Program

Patient support

• Through the online MySupport360® program, Myriad connects your patients with a wealth of helpful information, expert guidance, and the ability to share their experiences with others

Medical support

• A team of highly trained medical specialists is available for consultation
• Support is accessible by phone, e-mail, and in person

Visit www.MyriadPro.com for extensive medical education and resources